A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension

American Journal of Hypertension

Volumn 11, Issue 4 I, 1998, Pages 454-461

  Lacourcière, Yves ^a   Pool, James L ^b   Svetkey, Laura ^c   Gradman, Alan H ^d   Larochelle, Pierre ^e   De Champlain, Jacques ^f   Smith, William B ^g  

^a LAVAL UNIVERSITY   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WESTERN PENNSYLVANIA HOSPITAL   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g Louisiana Cardiovascular Research Center   (United States)

Author keywords

Ambulatory blood pressure; Hypertension; Nonpeptide angiotensin II receptor antagonist; Tasosartan; Trough to peak ratio

Indexed keywords

PLACEBO; TASOSARTAN;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031777356     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00487-1     Document Type: Article

References (12)

1. Laragh JH. Historical perspective on renin system blockade in the treatment of hypertension. Am J Hypertens. 5:1992;207S-208S.
2. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 25:1995;1345-1350.
3. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 155:1995;405-411.
4. Ellingboe JW, Antane M, Nguyen TT, et al. Pyrido(2,3-α)pyrimidine angiotensin II antagonists. J Med Chem. 37:1994;542-550.
5. Chen LSK, Ling HP, Cuddy M, Colatsky TJ. Pharmacological characterization of two new angiotensin II receptor antagonists WAY 126277 and WAY 125756 (abst). Circulation. 88:(4 part 2):1993;I433.
6. Hartupee D, White Y, Roynyak J, et al. In vivo characterization of ANA 756, an angiotensin II (AII) antagonist (abst). FASEB J. 8:1994;A5.
7. Steinhäuslin F, Buelin T, Bouissou P, et al. Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers (Abst). Clin Pharm. 55:(2):1994;205.
8. Graettinger WF, Lipson JL, Cheung DG, Weber MA. Validation of portable non invasive blood pressure monitoring devices comparison with intra-arterial and sphygmomanometer measurements . Am Heart J. 116:1988;1155-1160.
9. Neutel JM, Smith DHG, Ram CVS, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 94:1993;181-187.
10. O'Brien E, O'Malley K, Cox J, Stanton A. Ambulatory blood pressure monitoring in the evaluation of drug efficacy. Am Heart J. 121:1991;999-1006.
11. Weber MA, Cheung DG, Graettinger WF, Lipson JL. Characterization of antihypertensive therapy by whole-day blood pressure monitoring. JAMA. 259:1988;3281-3285.
12. Lacourcière Y, Poirier L, Dion D, Provencher P. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol. 65:1990;467-472.